Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked and the submission will be completed in July 2022.
Our product has been developed based on the reference brand Brintellix 20mg which is indicated for the treatment of Anti-Depression and sold at around $1.7bn in 2021, according to IQVIA. This product is being developed as part of a strategic collaboration with one of our partners.
Based on our positive progress, we expect to be amongst the first-to-file / first-to-market companies in all our major markets.